Genmab — Juni 2018
-
Journal of Immunology. 1. maj, 2018: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich rheumatoid arthritis, pre-rheumatoid arthritis and systemic lupus erythematosus. "Taken together, our data provides rationale for daratumumab in the treatment of RA and SLE"
-
Måske det får dem til at se fordelen ved at købe Genmab.
-
Daratumumab for the Treatment of Multiple Myeloma - https://www.frontiersin.org/articles/10.3389/fimmu.2018.01228/full
-
"If further substantiated that an implication may be that daratumumab should be part of any anti-myeloma treatment. Given the pleiotropic effects of daratumumab, it is in fact difficult to imagine how a myeloma patient can become truly refractory to daratumumab."
-
Mere fra Journal of Immunology. 1. maj, 2018: Dara i CLL, http://www.jimmunol.org/content/200/1_Supplement/58.17
-
Yes, it looks like Mayo-people all over. Ohio State is currently running a combo with Ibrutinib https://www.clinicaltrials.gov/ct2/show/NCT03447808?term=daratumumab+cll&rank=1
-
Desværre fortsætter stigningen ikke i dag. TA mæssigt, er det vel vigtigt,
vi lukker over kurs 1000. -
hehe
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

